1. Introduction {#sec1-ijms-18-00081}
===============

Solid pseudopapillary tumor (SPT, also known as solid pseudopapillary neoplasm) is an uncommon but distinct pancreatic tumor with a reported incidence of approximately 2% of all exocrine pancreatic neoplasms \[[@B1-ijms-18-00081]\]. Most SPTs have been diagnosed in females with a mean age of 28 years \[[@B2-ijms-18-00081],[@B3-ijms-18-00081]\], and have always presented characteristics of indolent biological behavior and high rates of long-term survival \[[@B1-ijms-18-00081],[@B2-ijms-18-00081]\]. Surgical resection resulted in better outcome even in metastatic disease \[[@B4-ijms-18-00081]\]. Although multiple studies have allowed insight into SNPs genetic pathogenesis, comprehensive exploration of the variations of the gene coding region has not been performed \[[@B4-ijms-18-00081],[@B5-ijms-18-00081]\].

Variations of *KRAS*, *SMAD4*, *TP53* and *CDKN2A* have never been detected in SPT \[[@B5-ijms-18-00081],[@B6-ijms-18-00081]\], which is different to the molecular changes seen in some malignancies such as pancreatic cancer. However, the significance of Wnt signaling with β-catenin mutations in SPT has been determined \[[@B4-ijms-18-00081]\]. Almost all patients with SPT have mutations of the somatic β-catenin coding gene (*CTNNB1*), and numerous proteins associated with β-catenin have been detected as dysfunctional \[[@B5-ijms-18-00081],[@B7-ijms-18-00081],[@B8-ijms-18-00081]\]. Normally, neoplasm development has been described as regulated by multiple events instead of a single key protein \[[@B9-ijms-18-00081]\]. In SPT, other gene variations may have a synergistic effect on the biological behavior of the neoplasm.

In the present study, we applied whole exome sequencing to investigate the cause of the genetic variation of solid pseudopapillary tumor. By identifying the prominent variations of indels and SNPs, 95 events were detected which were observed to impact gene function. These events have enabled us to describe the potential molecular pathways involved in the pathogenesis of this disease.

2. Results {#sec2-ijms-18-00081}
==========

We performed whole-exome sequencing of paired SPT tissues from nine patients with SPT confirmed by pathology, including four males (aged from 26 to 51 years) and five females (aged from 25 to 43 years). All patients were diagnosed with pancreatic cystic, solid, or cystic-solid lesions. The clinical features of seven patients with non-metastatic disease and two patients with metastases are listed in [Table 1](#ijms-18-00081-t001){ref-type="table"}. Each set of paired sequencing data from the neoplasm and adjacent tissues were compared to detect the SPT-specific gene variations.

2.1. Mononucleotide Variation in Solid Pseudopapillary Tumor of the Pancreas (SPT) {#sec2dot1-ijms-18-00081}
----------------------------------------------------------------------------------

We performed an overview of all the non-synonymous mutations among the coding regions of each of the samples, and 65 prominent single base changes (SNPs) were detected ([Table 2](#ijms-18-00081-t002){ref-type="table"}, [Figure 1](#ijms-18-00081-f001){ref-type="fig"}). The variations were detected in 56 genes, and *CTNNB1*, a β-catenin protein-coding gene, was found to be mutated in all the patients. In addition, no other general single sequence variation was found ([Figure 1](#ijms-18-00081-f001){ref-type="fig"}A). Almost all of the variations in the alleles were heterozygous mutations, and only one homozygous mutated base in the *MED12* gene had occurred (in patient number 1) ([Table 2](#ijms-18-00081-t002){ref-type="table"}). Although the sample size investigated was limited, comparison of the incidence of SNPs between each case suggested that more SNPs events occurred in patients with distant metastases (*p* \< 0.01) ([Figure 1](#ijms-18-00081-f001){ref-type="fig"}B). Interestingly, the patients with larger tumor size (diameter \>100mm) had more SNPs detected than others with smaller size ([Table 1](#ijms-18-00081-t001){ref-type="table"}, [Figure 1](#ijms-18-00081-f001){ref-type="fig"}B) (*p* \< 0.01). In addition, the two patients with metastatic disease were older than the others. Moreover, analysis of the SNPs location showed that more mononucleotide variation was distributed in chromosomes 2, 1, and 17 ([Figure 1](#ijms-18-00081-f001){ref-type="fig"}C).

2.2. Insertions and Deletions in SPT {#sec2dot2-ijms-18-00081}
------------------------------------

In total, 56 significant insertions and deletions (indels) in the DNA were detected in the nine subjects, and 41 known genes were associated with those indels ([Table 3](#ijms-18-00081-t003){ref-type="table"}). Functional annotation showed that a number of (25 of 56) indels would introduce a frame shift, and two indels would generate a splicing alteration ([Figure 1](#ijms-18-00081-f001){ref-type="fig"}A). We predicted that the impact of these sequence changes, 27 indels showing frame shift and/or splicing site changes, might be important in the biological activity of the cell, and that the other 29 events might play secondary roles ([Figure 2](#ijms-18-00081-f002){ref-type="fig"}B). Chromosome distribution showed that the regions of high impact were mostly located in chromosomes 19 and 20 ([Figure 2](#ijms-18-00081-f002){ref-type="fig"}C). We also compared the genes involved in indels and SNPs, and only one common gene, TBP (TATA-box binding protein), was detected.

2.3. The Network of Indels and Single Nucleotide Polymorphisms (SNPs) Related Genes {#sec2dot3-ijms-18-00081}
-----------------------------------------------------------------------------------

In neoplasm progression, indels and SNPs cause gene functional variation \[[@B10-ijms-18-00081]\], and gene expression also regulates important cellular activities. We compared the combined set of gene variations with previously reported abnormally expressed genes \[[@B5-ijms-18-00081]\] in SPT, and the results showed an overlap of two genes, *CTNNB1* and *AR* ([Figure 3](#ijms-18-00081-f003){ref-type="fig"}A, bottom Venny schedule). Additionally, *CTNNB1* had the highest rate of variation events in the combined set. ([Figure 3](#ijms-18-00081-f003){ref-type="fig"}B). Phosphoproteins was shown as the biggest cluster based on the functions and pathway correlations ([Figure 3](#ijms-18-00081-f003){ref-type="fig"}C). Details of each cluster are listed in [Table 4](#ijms-18-00081-t004){ref-type="table"}.

According to annotating protein--protein interaction using String database, *CTNNB1* was shown as a hub and directly connected with another six genes with a high confidence (score \> 0.90) ([Figure 3](#ijms-18-00081-f003){ref-type="fig"}D). PKD1 (Protein Kinase D1), a serine-threonine kinase, has been reported to modulate the β-catenin functions in colon cancer \[[@B11-ijms-18-00081]\]. The deubiquitination protein USP9X was shown to be required for lymphocyte activation \[[@B12-ijms-18-00081]\]. EP400 is an E1A binding protein and deposits the histone variant H3.3 into chromatin alongside histone H2AZ and contributes to gene regulation \[[@B13-ijms-18-00081]\]. The *HTT* gene coding for Huntington protein, is mutated in Huntington's disease but is ubiquitously expressed, and mutant *HTT* also influences cancer progression \[[@B14-ijms-18-00081]\]. Additionally, other protein--protein connections such as KCNC3 vs. KCNQ5, ATXN3 vs. ATXN2, TFAM vs. TFB1M, and FGGY vs. SHPK also showed stronger paired connections.

3. Discussion {#sec3-ijms-18-00081}
=============

The low incidence of solid pseudopapillary tumor of the pancreas determined that large-scale susceptibility gene screening was unachievable. To explore the potential pathogenic gene, we describe here the first paired whole genome sequencing of SPT in the Chinese population with a limited sample size (nine neoplasm tissues vs. nine adjunct tissues). Our data revealed that multiple protein-coding related variations participated in SPT disease progression. However, gene variation distributions in each case are widely divergent. Even though *CTNNB1* mutations were detected throughout all patients, the mutated nucleic acid sites were different ([Table 2](#ijms-18-00081-t002){ref-type="table"}). Those diversified variations suggested that SPT is a multi-heterogeneity disease, which might be caused by the dysregulation in the development of pancreas.

The function network suggests that *CTNNB1* may work as a hub and be closely connected with other gene variations, such as *USP9X*, *EP400*, *PDK1*, *MED12*, *HTT* and *AR*. Some of those genes have been reported to play an important role in other cancers \[[@B15-ijms-18-00081],[@B16-ijms-18-00081],[@B17-ijms-18-00081]\]. Both indels and SNP sets showed TBP (TATA-box binding) dysfunction ([Figure 1](#ijms-18-00081-f001){ref-type="fig"}A), and this might cause the hallmarks of oncogene-induced replication stress, including replication fork slowing, DNA damage, and senescence \[[@B18-ijms-18-00081]\]. Comparing similarities of gene abnormality with former expression data \[[@B5-ijms-18-00081]\], we noticed that CTNNB1 and AR (androgen receptor) were in the intersection, suggesting that AR signaling was also closely related \[[@B19-ijms-18-00081]\]. Most colon cancer development and progression is involved in dysregulation of the β-catenin signaling pathway, and PKD1 was previously reported to directly interact with β-catenin, and to attenuate β-catenin transcriptional activity by decreasing nuclear β-catenin levels, which eventually suppressed colon cancer growth \[[@B11-ijms-18-00081]\].

As the core portion in the co-connected network and the focus of multiple studies, the Wnt/β-catenin (*CTNNB1* coding) pathway played an important role to facilitate carcinogenesis through regulated or unregulated changes in gene transcription \[[@B4-ijms-18-00081],[@B7-ijms-18-00081],[@B20-ijms-18-00081],[@B21-ijms-18-00081]\]. Although considerable detail had revealed that the upstream factors induced activation of β-catenin in the cytoplasm, the mechanism by which β-catenin is involved with connected gene variations in different neoplasms is much less known \[[@B22-ijms-18-00081]\]. In this study, we detected that β-catenin was mutated in all neoplasms studied (100%), and that this frequency was higher than previously reported (approximate 90%), suggesting that *CTNNB1* mutation is ubiquitous in SPT patients. The detection level may depend on detection methods. Moreover, functionally associating or physically binding with other candidates indicated that the effect of β-catenin might require assistant factors \[[@B15-ijms-18-00081],[@B23-ijms-18-00081]\].

Among the studied patients, only patients 5 and 11 showed a distant metastasis phenotype. We detected many more SNPs were distributed in the metastatic disease compared to non-metastatic cases. Although this interesting phenomenon requires extended study, it suggests that enriched mutation might accelerate metastatic disease. Analogously, enriched mutation was also potentially related to larger tumor size. These discoveries have not been reported previously.

Based on functional annotations of indels adding SNPs genes, phosphoproteins were shown as the biggest cluster, revealing that most protein variations participated in signaling transduction. For instance, USP9x, a deubiquitinase, and connected with CTNNB1 as shown in the network, has been reported to be required for PKCβ kinase activity and induced the cell survival and tumor-promoting activities of Notch signaling in cancer \[[@B12-ijms-18-00081],[@B24-ijms-18-00081]\]. Additionally, significant enrichment of candidates also indicates an involvement in coiled-coil protein and mental retardation, suggesting the variation might cause structural abnormality and nervous system metastasis. Distinguishing with most previously study, we investigated the broad spectrum genes variations in SPT. All detected genetic variations need to be further verified.

4. Materials and Methods {#sec4-ijms-18-00081}
========================

4.1. Patients and Tissues {#sec4dot1-ijms-18-00081}
-------------------------

Eleven patients diagnosed with SPT and who underwent radical surgery in Shanghai Cancer Center, Fudan University (Shanghai, China), between 2010 and 2014 were selected for this study. SPT is circumscribed, solid, cystic masses and the pathology microscopic characteristic is typical pseudopapillae composed of central fibrovascular stalks embosomed by discohesive tumor cells with monotonous nuclei, absent nuclear pleomorphism, and low mitotic activity ([Figure S1](#app1-ijms-18-00081){ref-type="app"}) \[[@B25-ijms-18-00081],[@B26-ijms-18-00081]\]. The diagnoses of the resected tissues were confirmed by the Department of Pathology and 2 specimens (patient number 4 and patient number 6) were excluded because of the limited content of tumor cells (\<30%). Clinical information regarding patient age, gender, TNM stage, tumor size, tumor location, and metastatic of non-metastatic disease, were collected from medical record files. TNM staging of each patient was based on AJCC (American Joint Committee on Cancer) classification criterion. Paired carcinoma and adjacent tissue specimens from the patients were frozen in liquid nitrogen and then store at −80 °C. The study was approved by the ethics committee of Fudan University Shanghai Cancer Center (ethical approval number: 050432-4-1212B, ethical approval date: 24 December 2012). Before the project began, written informed consent from all 9 patients was obtained, and the clinical events were evaluated based on the original histopathology reports and clinical records.

4.2. DNA Extraction and Exome Sequencing {#sec4dot2-ijms-18-00081}
----------------------------------------

Before DNA Extraction, frozen sections of each tissue were stained with H&E to ensure the tumor cell number was more than 25% in the tissue. Genomic DNA from 9 tissues from each patient was extracted using a DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany). The exome of the genomic DNA was captured and sequenced using Agilent SureSelect system (BGI Co., Shenzhen, China) according to the manual. The DNA sample of genomic was fragmented randomly. The 150- to 200-bp fragments was utilized for the library and the adaptors were subsequently ligated to the fragments at both ends. The adapter-ligated templates were purified according to Agencourt AMPure SPRI beads (Beckmancoulter, Brea, CA, USA). For enrichment, the extracted DNA was amplified by LM-PCR (ligation-mediated PCR), purified, and hybridized to the SureSelect Biotinylated RNA Library (BAITS) (ABI, Waltham, MA, USA). After 24 h incubation, hybridized fragments were bound to the streptavidin beads whereas non-hybridized fragments were washed out. To estimate the magnitude of enrichment, captured LM-PCR products were analyzed by Agilent 2100 Bioanalyzer (Agilent Technologies, San Jose, CA, USA). Subsequently, the captured library was loaded on a Hiseq2000 platform (Illumina, San Diego, CA, USA) and sequenced in high-throughput with depth of more than 100× to ensure that each sample met the desired average sequencing depth. Raw image files were processed by Illumina basecalling Software 1.7 (Illumina) and the sequences information were generated as 90/100 bp pair-end reads. Representative variations of SNPs and indels were subsequently validated by Sanger sequencing ([Figure S2](#app1-ijms-18-00081){ref-type="app"}).

4.3. Read Mapping and Standard Bioinformatics Analysis {#sec4dot3-ijms-18-00081}
------------------------------------------------------

The sequencing data (raw data) generated from the Illumina software (Illumina basecalling Software 1.7) was needed to conduct cleaning and mapping. The adapter sequence in the raw data and low quality sequences which had too many unknown bases or low base quality were excluded. Clean data was produced and aligned by BWA (<http://biobwa.sourceforge.net/>) and formatted the sequence into binary BAM files. The BAM format files were established mate information of the alignment, added read group information and removed duplicate reads caused by PCR. Clean reads were processed by mapped to the reference human genome (GRCh37/hg19) from UCSC database (<http://genome.ucsc.edu/>) using SOAPalinger (<http://soap.genomics.org.cn/index.html>). Single Nucleotide Polymorphisms (SNPs) were detected according to SOAPsnp (<http://soap.genomics.org.cn/soapsnp.html>). Indels were aligned to the reference human genome from UCSC using BWA and further conduct with the Genome Analysis Toolkit (GATK v1.6) for recalling. Variants in the non-coding region and synonymous mutations were removed. SNPs and indels with higher frequency (\>0.5%) noted in dbSNP (<http://www.ncbi.nlm.nih.gov/projects/SNP/>), 1000 Genomes (<ftp://www.1000genome.org>), HapMap were also filtered out. Quality Control (QC) was processed in the steps of the clean data, the alignment, and the identified variant.

4.4. Exome Homozygosity Mapping {#sec4dot4-ijms-18-00081}
-------------------------------

Large stretches of the homozygous region were detected using the whole genome sequencing data. As markers to create a genetic map, all the autosomal dbSNP sites and novel SNPs that had ≥20-fold coverage of the exome target regions were examined. For the homozygous markers selection, variants with ≥95% of all reads displaying an identical SNP allele and covering at least 5-fold of the region were taken into consideration; for heterozygous markers selection, SNPs with 30% to 70% of all variation reads and which covered at least 10-fold were taken into consideration. The other SNPs with \<30% or with 70%--95% variation reads were considered ambiguous. Perl script was utilized for statistical analysis of the distribution of map markers along the genome. A window of 500 markers, containing a maximum of 2 heterozygous markers and allowing a maximum gap between 2 adjacent markers of 500 KB, was adopted. A homozygous stretch by coalescence of all qualified windows with a minimum of 1 MB in length identified as a genomic region.

4.5. Cluster and Network {#sec4dot5-ijms-18-00081}
------------------------

Each of the genes detected in the neoplasms with prominent SNPs and indels was functionally annotated and clustered by David database (<https://david.ncifcrf.gov>). After importing the genes list into String database (<http://www.string-db.org>), the high confidence (\>0.7) connection between genes was presented, which might be co-mentioned or mutually bound.

4.6. Statistical Analysis {#sec4dot6-ijms-18-00081}
-------------------------

Statistical analysis was performed using SPSS software (v13.0, Chicago, IL, USA). Data were analyzed and statistically assessed by Fisher's exact tests. *p* \< 0.01 was considered to be significant for all statistical analyses.

5. Conclusions {#sec5-ijms-18-00081}
==============

In the current study, we conducted whole exome sequencing in 9 SPT patients, which detected 54 SNPs and 41 indels of prominent variations in total. Multiple SNPs with a higher count was found to correlate with adverse clinical manifestations. In addition to be detected throughout all cases, *CTNNB1* mutation was presented to potentially collaborate with other gene variations. The aberration events involved in other cancers also showed the potential to stimulate the progression of SPT. This work revealed an insight into the variation of the gene encoding regions might partly reflect the potential molecular mechanism of SPT.

This study was jointly funded by the National Science Foundation for Distinguished Young Scholars of China (No. 81625016), the National Natural Science Foundation of China (No. 81372649, 81172276, 81370065, and 813726 53), Shanghai Municipal Commission of Health and Family Planning scientific research (20144Y0170), and basic research projects of the Science and Technology Commission of Shanghai Municipality (15JC1401200).

Supplementary materials can be found at [www.mdpi.com/1422-0067/18/1/81/s1](www.mdpi.com/1422-0067/18/1/81/s1).
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ijms-18-00081-t001_Table 1

###### 

Clinicopathological characteristics of patients.

  Patients   Gender   Age (Years)   Size (mm)   TNM Stage   Location        Distant Metastasis (Yes/No)   CA19-9 Value   Surgical Procedures
  ---------- -------- ------------- ----------- ----------- --------------- ----------------------------- -------------- -------------------------
  1          male     35            18          I           head            No                            no abnormal    distal pancreatectomy
  2          male     33            50          II          body and tail   No                            no abnormal    distal pancreatectomy
  3          male     26            70          II          body and tail   No                            no abnormal    distal pancreatectomy
  5          female   43            108         II          head            Yes                           no abnormal    total pancreatectomy
  7          female   30            45          II          body and tail   No                            no abnormal    distal pancreatectomy
  8          female   31            45          II          head            No                            no abnormal    pancreaticoduodenectomy
  9          female   25            50          II          body and tail   No                            no abnormal    distal pancreatectomy
  10         female   25            NA          II          head            No                            no abnormal    pancreaticoduodenectomy
  11         male     51            138         IV          body and tail   Yes                           no abnormal    distal pancreatectomy

ijms-18-00081-t002_Table 2

###### 

Information of prominent SNPs in each patient.

  Samples           Gene         Biotype                     Transcript                 Codon     Chromosome   Alleles
  ----------------- ------------ --------------------------- -------------------------- --------- ------------ ---------
  Patient_01        *C1orf100*   Missense                    NM_001012970:p.Tyr78Cys    tAt/tGt   chr01        het
  *CTNNB1*          Missense     NM_001098209:p.Asp32Tyr     Gac/Tac                    chr03     het          
  *MED12*           Missense     NM_005120:p.Arg1295Cys      Cgt/Tgt                    chrX      hom          
  *MYO1E*           Missense     NM_004998:p.Ser179Arg       agT/agG                    chr15     het          
  *SOS2*            Missense     NM_006939:p.Leu793Ile       Ctt/Att                    chr14     het          
  *UNC13C*          Missense     NM_001080534:p.Lys1395Met   aAg/aTg                    chr15     het          
  Patient_02        *CTNNB1*     Missense                    NM_001098209:p.Asp32Gly    gAc/gGc   chr03        het
  *H2AFX*           Missense     NM_002105:p.Leu98Arg        cTg/cGg                    chr11     het          
  *NEB*             Missense     NM_001164507:p.Asp5797Asn   Gat/Aat                    chr02     het          
  *SHPK*            Missense     NM_013276:p.Glu477Asp       gaA/gaC                    chr17     het          
  Patient_03        *CTNNB1*     Missense                    NM_001098209:p.Gly34Arg    Gga/Aga   chr03        het
  *KCMF1*           Missense     NM_020122:p.Arg257His       cGt/cAt                    chr02     het          
  Patient_05        *CTNNB1*     Missense                    NM_001098209:p.Ser37Pro    Tct/Cct   chr03        het
  *DOCK8*           Missense     NM_203447:p.Val245Met       Gtg/Atg                    chr09     het          
  *LCE1F*           Missense     NM_178354:p.Arg83His        cGt/cAt                    chr01     het          
  *LRCH1*           Missense     NM_001164211:p.His745Arg    cAt/cGt                    chr13     het          
  *N4BP2*           Missense     NM_018177:p.Thr92Ile        aCc/aTc                    chr04     het          
  *PKD1*            Missense     NM_001009944:p.Arg4249Cys   Cgc/Tgc                    chr16     het          
  *PKHD1L1*         Missense     NM_177531:p.Ile2532Ser      aTt/aGt                    chr08     het          
  *PLAU*            Missense     NM_002658:p.His224Gln       caC/caG                    chr10     het          
  *PRHOXNB*         Missense     NM_001105577:p.Gly116Arg    Ggt/Cgt                    chr13     het          
  *TUSC5*           Missense     NM_172367:p.Ser93Thr        Tcc/Acc                    chr17     het          
  Patient_07        *ACTL8*      Missense                    NM_030812:p.Arg48His       cGt/cAt   chr01        het
  *ADCK5*           Missense     NM_174922:p.Arg449His       cGc/cAc                    chr08     het          
  *ARMCX1*          Missense     NM_016608:p.Cys144Tyr       tGc/tAc                    chrX      het          
  *C16orf62*        Missense     NM_020314:p.Ala53Glu        gCg/gAg                    chr16     het          
  *CCT2*            Missense     NM_006431:p.Gly98Asp        gGc/gAc                    chr12     het          
  *CTNNB1*          Missense     NM_001098209:p.Ser33Cys     tCt/tGt                    chr03     het          
  *WDR62*           Missense     NM_001083961:p.Val407Ile    Gtt/Att                    chr19     het          
  Patient_08        *CLIP1*      Missense                    NM_001247997:p.Ile450Val   Att/Gtt   chr12        het
  *CTNNB1*          Missense     NM_001098209:p.Ser37Phe     tCt/tTt                    chr03     het          
  *MAP2K1*          Missense     NM_002755:p.Leu42His        cTt/cAt                    chr15     het          
  *NEK8*            Missense     NM_178170:p.Asp530Asn       Gac/Aac                    chr17     het          
  *OR4C6*           Missense     NM_001004704:p.Phe104Ser    tTc/tCc                    chr11     het          
  *ROM1*            Missense     NM_000327:p.Ala265Glu       gCa/gAa                    chr11     het          
  *SETBP1*          Missense     NM_015559:p.Tyr1327Cys      tAt/tGt                    chr18     het          
  *SLC26A10*        Missense     NM_133489:p.Val488Met       Gtg/Atg                    chr12     het          
  *SNTG1*           Missense     NM_018967:p.Arg202Gln       cGa/cAa                    chr08     het          
  Patient_09        *CTNNB1*     Missense                    NM_001098209:p.Ser37Phe    tCt/tTt   chr03        het
  *DDX42*           Missense     NM_007372:p.Thr581Ala       Acc/Gcc                    chr17     het          
  *TBP*             Missense     NM_003194:p.Thr106Ala       Acg/Gcg                    chr06     het          
  *USP9X*           Missense     NM_001039590:p.Asn2098Ser   aAt/aGt                    chrX      het          
  Patient_10        *CTNNB1*     Missense                    NM_001098209:p.Ser33Phe    tCt/tTt   chr03        het
  *FAM89A*          Missense     NM_198552:p.Ser175Cys       tCc/tGc                    chr01     het          
  Patient_11        *BCAP31*     Missense                    NM_001139457:p.Ile190Val   Att/Gtt   chrX         het
  *BHMT*            Missense     NM_001713:p.Asp105Asn       Gac/Aac                    chr05     het          
  *C16orf3*         Missense     NM_001214:p.Val60Ile        Gta/Ata                    chr16     het          
  *C16orf3*         Missense     NM_001214:p.Ser57Gly        Agc/Ggc                    chr16     het          
  *COL5A3*          Missense     NM_015719:p.Gly533Val       gGa/gTa                    chr19     het          
  *CRAMP1L*         Missense     NM_020825:p.Pro818Thr       Ccc/Acc                    chr16     het          
  *CTNNB1*          Missense     NM_001098209:p.Asp32Tyr     Gac/Tac                    chr03     het          
  *E2F7*            Missense     NM_203394:p.Phe873Val       Ttt/Gtt                    chr12     het          
  *FCGBP*           Missense     NM_003890:p.Gly4778Asp      gGc/gAc                    chr19     het          
  *FGGY*            Missense     NM_001113411:p.Ser21Asn     aGt/aAt                    chr01     het          
  *KEL*             Missense     NM_000420:p.Arg393Gln       cGg/cAg                    chr07     het          
  *KIAA0586*        Missense     NM_001244189:p.Lys953Ile    aAa/aTa                    chr14     het          
  *KRT16*           Missense     NM_005557:p.Gly69Cys        Ggc/Tgc                    chr17     het          
  *PEX10*           Missense     NM_153818:p.Leu221His       cTc/cAc                    chr01     het          
  *PTOV1*           Missense     NM_017432:p.Lys212Met       aAg/aTg                    chr19     het          
  *SIRPB2*          Missense     NM_001122962:p.Gly94Arg     Ggg/Agg                    chr20     het          
  *SPINLW1-WFDC6*   Missense     NM_001198986:p.Glu141Lys    Gaa/Aaa                    chr20     het          
  *THAP4*           Missense     NM_015963:p.Gly111Ser       Ggt/Agt                    chr02     het          
  *TMEM99*          Missense     NM_001195386:p.Asp195Asn    Gac/Aac                    chr17     het          
  *TYR*             Missense     NM_000372:p.Thr292Met       aCg/aTg                    chr11     het          
  *UMODL1*          Missense     NM_173568:p.Asp814Glu       gaC/gaG                    chr21     het          

Codon: Capital letter represents the variational base and lowercase represents the uniformity.

ijms-18-00081-t003_Table 3

###### 

Impact and functional annotations of detected Indel variations.

  Impact     Function   Chr     Gene          Reference                      Observation        Alleles
  ---------- ---------- ------- ------------- ------------------------------ ------------------ ---------
  High       FS         chr01   *AHDC1*       T                              TG                 het
  High       FS         chr01   *LRRIQ3*      G                              GT                 het
  High       FS         chr10   *NOC3L*       AT                             A                  het
  High       FS         chr10   *TFAM*        CA                             C                  het
  High       FS         chr12   *TDG*         G                              GA                 het
  High       FS         chr14   *CCNK*        G                              GC                 het
  High       FS         chr14   *PAPOLA*      TG                             T                  het
  High       FS         chr16   *IRX5*        AGG                            A                  het
  High       FS         chr17   *ACSF2*       T                              TAA                het
  High       FS         chr17   *KRT10*       CCGCCG                         C                  het
  High       FS         chr17   *KRT10*       TG                             T                  het
  High       FS         chr19   *CAPN12*      G                              GC                 het
  High       FS         chr19   *KCNC3*       C                              CG                 het
  High       FS         chr02   *SNED1*       A                              AC                 het
  High       FS         chr20   *C20orf132*   GACCT                          G                  het
  High       FS         chr20   *C20orf132*   GC                             G                  het
  High       FS         chr20   *C20orf132*   GAGGAGTT                       G                  het
  High       FS         chr20   *C20orf132*   CG                             C                  het
  High       FS         chr20   *C20orf132*   TGG                            T                  het
  High       FS         chr06   *TBP*         AGC                            A                  het
  High       FS         chr06   *TBP*         AG                             A                  het
  High       FS         chr06   *TFB1M*       CAA                            C                  het
  High       FS         chr09   *PHF2*        A                              AG                 het
  High       FS         chrX    *PLXNA3*      T                              TG                 het
  High       FS         chrX    *RBM10*       CA                             C                  het
  High       SSD        chr19   *KRI1*        CCATCA                         C                  het
  High       SSD        chr19   *KRI1*        CCATCA                         C                  het
  Moderate   C & D      chr11   *SCUBE2*      GGCA                           G                  het
  Moderate   C & D      chr12   *ATXN2*       GGCT                           G                  het
  Moderate   C & D      chr14   *MAP3K9*      GCCT                           G                  het
  Moderate   C & D      chr19   *SAFB2*       GTAC                           G                  het
  Moderate   C & D      chr02   *GIGYF2*      CACA                           C                  het
  Moderate   C & D      chr09   *TPRN*        TTCC                           T                  het
  Moderate   C & D      chrX    *AR*          AAGAGACTAGCCCCAG               A                  het
  Moderate   C & I      chr11   *KRTAP5-8*    T                              TCCG               het
  Moderate   C & I      chr14   *ATXN3*       C                              CCTG               het
  Moderate   C & I      chr14   *IRF2BPL*     C                              CTGCTGT            het
  Moderate   C & I      chr04   *HTT*         A                              AACAGCC            het
  Moderate   C & I      chr08   *ATAD2*       A                              ATCG               het
  Moderate   CD         chr16   *APOBR*       TGGGACAGCCTCAGGAGGGGAGGAGGCC   T                  het
  Moderate   CD         chr17   *KDM6B*       TCAC                           T                  het
  Moderate   CD         chr18   *MBD2*        CGCA                           C                  het
  Moderate   CD         chr19   *ARID3A*      GGGA                           G                  het
  Moderate   CD         chr04   *ADAM29*      GTGACACCCTCCCAGAGGCAACCTCAGT   G                  het
  Moderate   CD         chr06   *KCNQ5*       AGCG                           A                  het
  Moderate   CD         chr06   *TBP*         GCAA                           G                  het
  Moderate   CD         chr09   *RNF20*       TGTTGACTCTGAAGACTCA            T                  het
  Moderate   CI         chr10   *C10orf140*   C                              CCCTCCT            het
  Moderate   CI         chr12   *EP400*       A                              ACAG               het
  Moderate   CI         chr12   *EP400*       A                              ACAG               het
  Moderate   CI         chr12   *EP400*       G                              GCAA               het
  Moderate   CI         chr17   *KRTAP4-5*    T                              TGGCAGCAGCTGGGGC   het
  Moderate   CI         chr19   *ZNF814*      C                              CATA               het
  Moderate   CI         chr04   *HTT*         A                              ACCGCCGCCG         het
  Moderate   CI         chr06   *TBP*         A                              ACAG               het
  Moderate   CI         chr06   *TBP*         A                              ACAG               het

FS: frame shift, SSD: splice site donor, CD: codon deletion, CI: codon insertion, G & I: codon change plus codon insertion, G & D: codon change plus codon deletion, Chr: chromosome.
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###### 

Ontology terms and annotations of indels adding SNPs genes.

  Category           Term                                      Count   Genes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Benjamin        FDR
  ------------------ ----------------------------------------- ------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- ---------------
  Up keywords        Phosphoprotein                            56      *PLXNA3*, *KCNC3*, *TUSC5*, *E2F7*, *CCT2*, *CTNNB1*, *KCNQ5*, *MAP3K9*, *H2AFX*, *RBM10*, *AR*, *CCNK*, *C16ORF62*, *MED12*, *KRT10*, *KIAA0586*, *MBD2*, *LRCH1*, *KRT16*, *BHMT*, *NEK8*, *CLIP1*, *UNC13C*, *RNF20*, *GIGYF2*, *EP400*, *KDM6B*, *PTOV1*, *IRX5*, *THAP4*, *KEL*, *USP9X*, *NOC3L*, *N4BP2*, *TFAM*, *APOBR*, *PKD1*, *KRI1*, *DDX42*, *MAP2K1*, *HTT*, *MYO1E*, *ARID3A*, *ATAD2*, *DOCK8*, *SAFB2*, *ATXN2*, *ATXN3*, *PAPOLA*, *PHF2*, *KCMF1*, *WDR62*, *IRF2BPL*, *PLAU*, *TPRN*, *AHDC1*   0.004376        0.086018
  Up keywords        Coiled coil                               29      *LRRIQ3*, *THAP4*, *NOC3L*, *TBP*, *N4BP2*, *MAP3K9*, *PKD1*, *KRI1*, *DDX42*, *AR*, *MAP2K1*, *HTT*, *ATAD2*, *KRT10*, *KIAA0586*, *BCAP31*, *ATXN2*, *ATXN3*, *PHF2*, *KCMF1*, *LRCH1*, *IRF2BPL*, *KRT16*, *CLIP1*, *UNC13C*, *RNF20*, *GIGYF2*, *EP400*, *TPRN*                                                                                                                                                                                                                                                  0.003907        0.102373
  Up seqfeature      Compositionally biased region: Poly-Gln   10      *ATXN2*, *CCNK*, *AR*, *ATXN3*, *KCNC3*, *IRF2BPL*, *HTT*, *KIAA0586*, *TBP*, *EP400*                                                                                                                                                                                                                                                                                                                                                                                                                                1.95 × 10^−5^   4.58 × 10^−5^
  Up keywords        Mental retardation                        10      *IRX5*, *MAP2K1*, *WDR62*, *USP9X*, *SETBP1*, *MED12*, *DOCK8*, *CTNNB1*, *AHDC1*, *BCAP31*                                                                                                                                                                                                                                                                                                                                                                                                                          6.05 × 10^−4^   0.007916
  Goterm mf direct   GO:0003682\~chromatin binding             10      *TFAM*, *AR*, *NOC3L*, *ARID3A*, *MED12*, *ATAD2*, *MBD2*, *RNF20*, *EP400*, *KDM6B*                                                                                                                                                                                                                                                                                                                                                                                                                                 0.022881        0.147425
  Up keywords        Triplet repeat expansion                  6       *ATXN2*, *AR*, *ATXN3*, *IRF2BPL*, *HTT*, *TBP*                                                                                                                                                                                                                                                                                                                                                                                                                                                                      3.76 × 10^−5^   2.46 × 10^−4^

FDR: false discover rate.

[^1]: These authors contributed equally to this work.
